Viyash Scientific Appoints Two Carlyle Directors and Revises ESOP Pool

2 min read     Updated on 23 Apr 2026, 07:09 AM
scanx
Reviewed by
Radhika SScanX News Team
AI Summary

Viyash Scientific has strengthened its board with the appointment of two senior Carlyle group executives as Additional Non-Executive, Non-Independent Directors. The company also revised its Employee Stock Option Scheme pool, reducing it from 1,34,75,000 to 1,30,98,000 stock options under ESOP 2026.

powered bylight_fuzz_icon
38388344

*this image is generated using AI for illustrative purposes only.

Viyash Scientific has announced significant board changes with the appointment of two Additional Non-Executive, Non-Independent Directors representing the Carlyle group, along with revisions to its Employee Stock Option Scheme. The appointments were made based on recommendations from the Nomination and Remuneration Committee and approved during a board meeting held on April 22, 2026.

Dual Board Appointments

The company's Board of Directors approved the appointment of two senior executives from Carlyle group as Additional Directors with effect from April 22, 2026. Both appointments are subject to shareholder approval and the directors are liable to retire by rotation.

Director Details: Amit Jain Abhiroop Jayanthi
DIN: 06917608 10354445
Designation: Additional Non-Executive, Non-Independent Director Additional Non-Executive, Non-Independent Director
Current Role: Partner and Head of Carlyle India Advisors Managing Director, Asia Private Equity team at Carlyle
Effective Date: April 22, 2026 April 22, 2026

Professional Backgrounds

Amit Jain's Experience

Amit Jain serves as Partner and Head of Carlyle India Advisors, overseeing Carlyle's India operations and private equity team. He leads investment and portfolio company activities across technology, consumer, advanced manufacturing and industrial sectors. Jain joined Carlyle in 2021 after a decade at Blackstone India, where he served as Senior Managing Director in the Private Equity Group.

His career began with consulting at McKinsey & Company and operating roles at Unilever in India. He currently serves on the boards of several Carlyle portfolio companies, including Quest Global, Piramal Healthcare, VLCC, Highway Roop, Varmora Granito, and Strata Geosystems, Knack Global & Adastrra. Jain was recognized by The Economic Times as one of India's "40 Under 40" young business leaders in 2019.

Abhiroop Jayanthi's Profile

Abhiroop Jayanthi is a Managing Director and member of the Asia Private Equity team at Carlyle, which manages USD 465 billion of assets under management. He advises on investments in India focusing on healthcare, life sciences, advanced manufacturing, and industrial sectors.

With 15 years of private equity experience, Jayanthi previously served as Managing Director at Bain Capital, leading investments across healthcare, life sciences, technology, and industrials sectors. He was named one of India's most promising young corporate leaders by The Economic Times in 2014. Jayanthi holds an MBA from the Wharton Business School and earned his undergraduate degree in Industrial Engineering from IIT Delhi.

ESOP Pool Revision

The Board approved a revised Employee Stock Option Scheme pool under ESOP 2026. The total number of stock options was adjusted from the originally proposed 1,34,75,000 to 1,30,98,000 stock options based on the recommendation of the Nomination and Remuneration Committee.

ESOP Details: Information
Original Pool: 1,34,75,000 stock options
Revised Pool: 1,30,98,000 stock options
Scheme Name: Viyash Scientific Limited Employee Stock Option Scheme 2026

Strategic Significance

The appointment of both directors represents Carlyle group's continued involvement in Viyash Scientific's governance structure. According to the regulatory filing, both appointees have declared they are not debarred from holding director positions pursuant to any SEBI order or other authority. The Board meeting was conducted from 11:30 a.m. to 12:39 p.m. on April 22, 2026, with the company fulfilling its disclosure obligations under Regulation 30 of the SEBI Listing Regulations.

Historical Stock Returns for Viyash Scientific

1 Day5 Days1 Month6 Months1 Year5 Years
-2.30%-0.65%+15.00%+1.60%+39.11%-22.12%

What strategic initiatives might Carlyle pursue through Viyash Scientific given their focus on healthcare, technology, and advanced manufacturing sectors?

How could the reduced ESOP pool from 1.35 crore to 1.31 crore options impact employee retention and future talent acquisition strategies?

Will Carlyle's increased board representation signal potential changes in Viyash Scientific's expansion plans or acquisition strategy?

Viyash Scientific Limited Changes Domain Name and Updates Authorized Signatory Email IDs

1 min read     Updated on 20 Apr 2026, 03:07 PM
scanx
Reviewed by
Radhika SScanX News Team
AI Summary

Viyash Scientific Limited has changed its domain name from www.sequent.in to www.viyash.com and updated authorized signatory email addresses in compliance with SEBI regulations. The changes, effective immediately, were communicated to BSE and NSE on April 20, 2026, reflecting the company's transition from its former identity as Sequent Scientific Limited.

powered bylight_fuzz_icon
38223459

*this image is generated using AI for illustrative purposes only.

Viyash Scientific Limited has announced significant changes to its digital infrastructure, updating its domain name and authorized signatory email addresses in compliance with regulatory requirements.

Domain Name Transition

The company has transitioned from its previous domain www.sequent.in to the new domain www.viyash.com with immediate effect. This change reflects the company's rebranding from its former identity as Sequent Scientific Limited to Viyash Scientific Limited.

Regulatory Compliance Updates

In accordance with Regulation 30(5) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the company has updated the email addresses of its Directors and Key Managerial Personnel who are authorized to determine materiality of events and information for stock exchange disclosures.

Parameter: Previous Updated
Domain Name: www.sequent.in www.viyash.com
Investor Relations Email: investorrelations@sequent.in investorrelations@viyash.com
General Contact Email: - info@viyash.com

Corporate Information

The company maintains its registered office at 3rd Floor, Srivalli's Corporate, Plot No.290, Road No.6, Sy.No.33, 34P to 39, Guttala Begumpet, Jubilee Hills, Hyderabad, Shaikpet, Telangana, India-500033. The communication was signed by Yoshita Vora, Company Secretary & Compliance Officer, and submitted to both BSE Limited and National Stock Exchange of India Limited on April 20, 2026.

Stock Exchange Communication

The formal intimation was sent to both major stock exchanges where the company is listed, ensuring compliance with SEBI Listing Regulations. The company has requested both exchanges to take note of these changes for their records and future communications.

Historical Stock Returns for Viyash Scientific

1 Day5 Days1 Month6 Months1 Year5 Years
-2.30%-0.65%+15.00%+1.60%+39.11%-22.12%

What strategic business changes or market repositioning might have driven Viyash Scientific's complete rebranding from Sequent Scientific Limited?

How will the rebranding impact existing customer relationships and market recognition in the pharmaceutical/scientific industry?

Are there any planned changes to the company's product portfolio or business segments following this corporate identity transformation?

More News on Viyash Scientific

1 Year Returns:+39.11%